REGENXBIO Inc.
US ˙ NasdaqGS ˙ US75901B1070

SecurityRGNX / REGENXBIO Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership1,010,381 shares
Latest Disclosed Value $ 8,463,684
Dimensional Fund Advisors Lp reports 11.79% increase in ownership of RGNX / REGENXBIO Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 1,010,381 shares of REGENXBIO Inc. (US:RGNX) valued at $8,466,993 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 903,851 shares of REGENXBIO Inc.. This represents a change in shares of 11.79% during the quarter. The current value of the position is $6,143,116 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F REGENXBIO COM 75901B107 1,010,381 106,530 11.79 8,464 -34.97 0.0004
2026-02-12 2025-12-31 13F REGENXBIO COM 75901B107 903,851 -201,176 -18.21 13,014 22.04 0.0027
2025-11-12 2025-09-30 13F REGENXBIO COM 75901B107 1,105,027 -17,736 -1.58 10,664 15.69 0.0023
2025-08-12 2025-06-30 13F REGENXBIO COM 75901B107 1,122,763 -24,963 -2.17 9,219 12.31 0.0021
2025-05-13 2025-03-31 13F REGENXBIO COM 75901B107 1,147,726 -23,696 -2.02 8,208 -9.33 0.0020
2025-02-13 2024-12-31 13F REGENXBIO COM 75901B107 1,171,422 21,234 1.85 9,054 -24.97 0.0022
2024-11-07 2024-09-30 13F REGENXBIO COM 75901B107 1,150,188 42,735 3.86 12,066 -6.88 0.0029
2024-08-09 2024-06-30 13F REGENXBIO COM 75901B107 1,107,453 -89,620 -7.49 12,957 -48.63 0.0034
2024-05-10 2024-03-31 13F REGENXBIO COM 75901B107 1,197,073 -29,884 -2.44 25,222 14.52 0.0068
2024-02-07 2023-12-31 13F REGENXBIO COM 75901B107 1,226,957 34,385 2.88 22,025 12.19 0.0064
2023-11-09 2023-09-30 13F REGENXBIO COM 75901B107 1,192,572 -195,442 -14.08 19,633 -29.24 0.0064
2023-08-09 2023-06-30 13F REGENXBIO COM 75901B107 1,388,014 -148,117 -9.64 27,746 -4.48 0.0088
2023-05-12 2023-03-31 13F REGENXBIO COM 75901B107 1,536,131 176,543 12.99 29,046 96,720.00 0.0098
2023-02-09 2022-12-31 13F REGENXBIO COM 75901B107 1,359,588 105,487 8.41 31 -99.91 0.0091
2022-11-10 2022-09-30 13F REGENXBIO COM 75901B107 1,254,101 176,607 16.39 33,142 24.53 0.0127
2022-08-12 2022-06-30 13F REGENXBIO COM 75901B107 1,077,494 298,352 38.29 26,613 2.91 0.0095
2022-05-13 2022-03-31 13F REGENXBIO COM 75901B107 779,142 29,670 3.96 25,860 5.52 0.0080
2022-02-09 2021-12-31 13F REGENXBIO COM 75901B107 749,472 82,730 12.41 24,507 -12.32 0.0074
2021-11-12 2021-09-30 13F REGENXBIO COM 75901B107 666,742 -285,141 -29.96 27,950 -24.42 0.0090
2021-08-12 2021-06-30 13F REGENXBIO COM 75901B107 951,883 124,616 15.06 36,980 31.06 0.0117
2021-05-14 2021-03-31 13F REGENXBIO COM 75901B107 827,267 135,823 19.64 28,217 -10.04 0.0093
2021-03-08 2020-12-31 13F/A-2 REGENXBIO COM 75901B107 691,444 6,198 0.90 31,366 66.33 0.0113
2021-02-11 2020-12-31 13F REGENXBIO COM 75901B107 691,444 6,198 31,366 11,327.7320
2020-11-12 2020-09-30 13F REGENXBIO COM 75901B107 685,246 -16,631 -2.37 18,858 -27.05 0.0080
2020-08-13 2020-06-30 13F REGENXBIO COM 75901B107 701,877 15,078 2.20 25,850 16.23 0.0114
2020-05-14 2020-03-31 13F REGENXBIO COM 75901B107 686,799 -3,317 -0.48 22,240 -21.34 0.0116
2020-02-14 2019-12-31 13F REGENXBIO COM 75901B107 690,116 47,911 7.46 28,274 23.68 0.0103
2019-11-12 2019-09-30 13F REGENXBIO COM 75901B107 642,205 83,390 14.92 22,860 -20.36 0.0089
2019-08-13 2019-06-30 13F REGENXBIO COM 75901B107 558,815 108,836 24.19 28,705 11.32 0.0111
2019-08-12 2019-03-31 13F/A-2 REGENXBIO COM 75901B107 449,979 128,266 39.87 25,787 91.07 0.0103
2019-05-10 2019-03-31 13F REGENXBIO COM 75901B107 449,979 128,266 25,787
2019-02-26 2018-12-31 13F/A-1 REGENXBIO COM 75901B107 321,713 196,944 157.85 13,496 43.27 0.0061
2019-02-13 2018-12-31 13F REGENXBIO COM 75901B107 321,713 196,944 13,496
2018-11-13 2018-09-30 13F REGENXBIO COM 75901B107 124,769 106,198 571.85 9,420 606.68 0.0036
2018-08-10 2018-06-30 13F REGENXBIO COM 75901B107 18,571 18,571 1,333 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.